Cargando…

Evaluation and timing optimization of CT perfusion first pass analysis in comparison to maximum slope model in pancreatic adenocarcinoma

For implementation, performance evaluation and timing optimization of CT perfusion first pass analysis (FPA) by correlation with maximum slope model (MSM) in pancreatic adenocarcinoma, dynamic CT perfusion acquisitions of 34 time-points were performed in 16 pancreatic adenocarcinoma patients. Region...

Descripción completa

Detalles Bibliográficos
Autores principales: Vats, Neha, Mayer, Philipp, Kortes, Franziska, Klauß, Miriam, Grenacher, Lars, Stiller, Wolfram, Kauczor, Hans-Ulrich, Skornitzke, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313720/
https://www.ncbi.nlm.nih.gov/pubmed/37391443
http://dx.doi.org/10.1038/s41598-023-37381-w
_version_ 1785067176888107008
author Vats, Neha
Mayer, Philipp
Kortes, Franziska
Klauß, Miriam
Grenacher, Lars
Stiller, Wolfram
Kauczor, Hans-Ulrich
Skornitzke, Stephan
author_facet Vats, Neha
Mayer, Philipp
Kortes, Franziska
Klauß, Miriam
Grenacher, Lars
Stiller, Wolfram
Kauczor, Hans-Ulrich
Skornitzke, Stephan
author_sort Vats, Neha
collection PubMed
description For implementation, performance evaluation and timing optimization of CT perfusion first pass analysis (FPA) by correlation with maximum slope model (MSM) in pancreatic adenocarcinoma, dynamic CT perfusion acquisitions of 34 time-points were performed in 16 pancreatic adenocarcinoma patients. Regions of interest were marked in both parenchyma and carcinoma. FPA, a low radiation exposure CT perfusion technique, was implemented. Blood flow (BF) perfusion maps were calculated using FPA and MSM. Pearson’s correlation between FPA and MSM was calculated at each evaluated time-point to determine optimum timing for FPA. Differences in BF between parenchyma and carcinoma were calculated. Average BF for MSM was 106.8 ± 41.5 ml/100 ml/min in parenchyma and 42.0 ± 24.8 ml/100 ml/min in carcinoma, respectively. For FPA, values ranged from 85.6 ± 37.5 ml/100 ml/min to 117.7 ± 44.5 ml/100 ml/min in parenchyma and from 27.3 ± 18.8 ml/100 ml/min to 39.5 ± 26.6 ml/100 ml/min in carcinoma, depending on acquisition timing. A significant difference (p value < 0.0001) between carcinoma and parenchyma was observed at all acquisition times based on FPA measurements. FPA shows high correlation with MSM (r > 0.90) and 94% reduction in the radiation dose compared to MSM. CT perfusion FPA, where the first scan is obtained after the arterial input function exceeds a threshold of 120 HU, followed by a second scan after 15.5–20.0 s, could be used as a potential imaging biomarker with low radiation exposure for diagnosing and evaluating pancreatic carcinoma in clinical practice, showing high correlation with MSM and the ability to differentiate between parenchyma and carcinoma.
format Online
Article
Text
id pubmed-10313720
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-103137202023-07-02 Evaluation and timing optimization of CT perfusion first pass analysis in comparison to maximum slope model in pancreatic adenocarcinoma Vats, Neha Mayer, Philipp Kortes, Franziska Klauß, Miriam Grenacher, Lars Stiller, Wolfram Kauczor, Hans-Ulrich Skornitzke, Stephan Sci Rep Article For implementation, performance evaluation and timing optimization of CT perfusion first pass analysis (FPA) by correlation with maximum slope model (MSM) in pancreatic adenocarcinoma, dynamic CT perfusion acquisitions of 34 time-points were performed in 16 pancreatic adenocarcinoma patients. Regions of interest were marked in both parenchyma and carcinoma. FPA, a low radiation exposure CT perfusion technique, was implemented. Blood flow (BF) perfusion maps were calculated using FPA and MSM. Pearson’s correlation between FPA and MSM was calculated at each evaluated time-point to determine optimum timing for FPA. Differences in BF between parenchyma and carcinoma were calculated. Average BF for MSM was 106.8 ± 41.5 ml/100 ml/min in parenchyma and 42.0 ± 24.8 ml/100 ml/min in carcinoma, respectively. For FPA, values ranged from 85.6 ± 37.5 ml/100 ml/min to 117.7 ± 44.5 ml/100 ml/min in parenchyma and from 27.3 ± 18.8 ml/100 ml/min to 39.5 ± 26.6 ml/100 ml/min in carcinoma, depending on acquisition timing. A significant difference (p value < 0.0001) between carcinoma and parenchyma was observed at all acquisition times based on FPA measurements. FPA shows high correlation with MSM (r > 0.90) and 94% reduction in the radiation dose compared to MSM. CT perfusion FPA, where the first scan is obtained after the arterial input function exceeds a threshold of 120 HU, followed by a second scan after 15.5–20.0 s, could be used as a potential imaging biomarker with low radiation exposure for diagnosing and evaluating pancreatic carcinoma in clinical practice, showing high correlation with MSM and the ability to differentiate between parenchyma and carcinoma. Nature Publishing Group UK 2023-06-30 /pmc/articles/PMC10313720/ /pubmed/37391443 http://dx.doi.org/10.1038/s41598-023-37381-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Vats, Neha
Mayer, Philipp
Kortes, Franziska
Klauß, Miriam
Grenacher, Lars
Stiller, Wolfram
Kauczor, Hans-Ulrich
Skornitzke, Stephan
Evaluation and timing optimization of CT perfusion first pass analysis in comparison to maximum slope model in pancreatic adenocarcinoma
title Evaluation and timing optimization of CT perfusion first pass analysis in comparison to maximum slope model in pancreatic adenocarcinoma
title_full Evaluation and timing optimization of CT perfusion first pass analysis in comparison to maximum slope model in pancreatic adenocarcinoma
title_fullStr Evaluation and timing optimization of CT perfusion first pass analysis in comparison to maximum slope model in pancreatic adenocarcinoma
title_full_unstemmed Evaluation and timing optimization of CT perfusion first pass analysis in comparison to maximum slope model in pancreatic adenocarcinoma
title_short Evaluation and timing optimization of CT perfusion first pass analysis in comparison to maximum slope model in pancreatic adenocarcinoma
title_sort evaluation and timing optimization of ct perfusion first pass analysis in comparison to maximum slope model in pancreatic adenocarcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313720/
https://www.ncbi.nlm.nih.gov/pubmed/37391443
http://dx.doi.org/10.1038/s41598-023-37381-w
work_keys_str_mv AT vatsneha evaluationandtimingoptimizationofctperfusionfirstpassanalysisincomparisontomaximumslopemodelinpancreaticadenocarcinoma
AT mayerphilipp evaluationandtimingoptimizationofctperfusionfirstpassanalysisincomparisontomaximumslopemodelinpancreaticadenocarcinoma
AT kortesfranziska evaluationandtimingoptimizationofctperfusionfirstpassanalysisincomparisontomaximumslopemodelinpancreaticadenocarcinoma
AT klaußmiriam evaluationandtimingoptimizationofctperfusionfirstpassanalysisincomparisontomaximumslopemodelinpancreaticadenocarcinoma
AT grenacherlars evaluationandtimingoptimizationofctperfusionfirstpassanalysisincomparisontomaximumslopemodelinpancreaticadenocarcinoma
AT stillerwolfram evaluationandtimingoptimizationofctperfusionfirstpassanalysisincomparisontomaximumslopemodelinpancreaticadenocarcinoma
AT kauczorhansulrich evaluationandtimingoptimizationofctperfusionfirstpassanalysisincomparisontomaximumslopemodelinpancreaticadenocarcinoma
AT skornitzkestephan evaluationandtimingoptimizationofctperfusionfirstpassanalysisincomparisontomaximumslopemodelinpancreaticadenocarcinoma